Skip to content
Evigrade
CriticalAntiretroviral, HIV protease inhibitor×Prokinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)

Updated · Methodology

Mechanism

The liver metabolises atazanavir through CYP3A4, and atazanavir itself inhibits this enzyme, so levels of drugs cleared by the same pathway can rise (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). The atazanavir SmPC lists cisapride among CYP3A4 substrates with a narrow therapeutic margin. The boosters inhibit this enzyme even more: ritonavir is a stronger CYP3A4 inhibitor than atazanavir, and cobicistat is also a potent CYP3A inhibitor (atazanavir and atazanavir/cobicistat SmPCs, EMA). The documents give no study data with figures for this pair. According to the ritonavir SmPC, higher cisapride levels raise the risk of serious arrhythmias. The SmPC of clarithromycin, another CYP3A4 inhibitor, states that high cisapride levels can prolong the QT interval and cause ventricular arrhythmias (ritonavir SmPC, EMA; clarithromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Symptoms

The danger of this combination is serious heart rhythm disorders (atazanavir label, US Food and Drug Administration, FDA): QT prolongation, ventricular tachycardia, ventricular fibrillation and torsade de pointes (clarithromycin summary of product characteristics on its combination with cisapride, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while a ventricular arrhythmia causes sudden palpitations, dizziness or fainting. In some people atazanavir prolongs the PR interval: atrioventricular conduction changes are usually asymptomatic and generally limited to first-degree block, but second-degree block has also been reported (atazanavir FDA label).

Management

The combination is contraindicated. Cisapride is named in the contraindications of atazanavir with or without ritonavir and of atazanavir/cobicistat (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). With ritonavir, the ritonavir SmPC also contraindicates cisapride (ritonavir SmPC, EMA). The atazanavir SmPC asks prescribers to refer to the ritonavir SmPC before starting atazanavir with ritonavir (atazanavir SmPC, EMA). Cisapride is not in the Spanish medicines register CIMA, so the level of risk comes from the atazanavir and ritonavir documents. If a patient takes cisapride obtained in another country, do not prescribe atazanavir with it (atazanavir SmPC, EMA). Take special precautions when atazanavir is given with drugs that may prolong the QT interval or to people with bradycardia, congenital QT prolongation or electrolyte imbalance. In people with pre-existing second-degree or higher atrioventricular block or bundle branch block, use atazanavir with caution and only if the benefit outweighs the risk (atazanavir SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Cisapride